07:00 , Apr 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer G protein-coupled receptor 39 (GPR39); smoothened (SMO) In vitro studies suggest agonizing GPR39 could inhibit...
07:00 , Oct 11, 2010 |  BioCentury  |  Finance

Hallway Chatter

Hallway chatter Companies were busy rolling out their wish lists at the annual BIO Investor Forum in San Francisco last week. Among them was new Executive Chairman Kurt Graves of Intarcia Therapeutics Inc. (formerly BioMedicines Inc.),...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

Anchor Therapeutics, J&J deal

Anchor partnered with Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary to use Anchor's pepducin technology to discover and develop therapeutics targeting G protein-coupled receptors (GPCRs) for cancer and metabolic disorders. The deal includes Anchor's preclinical...
01:09 , Sep 10, 2010 |  BC Extra  |  Company News

Anchor, J&J in discovery deal

Anchor Therapeutics Inc. (Cambridge, Mass.) and Ortho-McNeil-Janssen Pharmaceuticals Inc. partnered to use Anchor's pepducin technology to discover and develop therapeutics targeting G protein-coupled receptors (GPCRs) for cancer and metabolic disorders. The deal includes Anchor's preclinical...
00:18 , Nov 12, 2005 |  BC Extra  |  Clinical News

Study links hormone with weight loss

Stanford researchers published in Science the discovery of the peptide hormone obestatin. In rats, the hormone decreased food intake, suppressed weight gain and slowed digestion. The researchers said obestatin is derived from the same...